Patients with non-HCC malignancies showed significantly older age (mean age: 62.6 vs. 56.2, P = 0.005), fewer underlying chronic hepatitis B background (73% vs. 91%, P = 0.025), lower alanine transaminase (ALT) (22.0 vs. 32.0, P = 0.002), α-fetoprotein (3.5 vs. 6.2, P = 0.019), PIVKA-II (26.0 vs. 47.0, P = 0.003) and higher CA19-9 (37.8 vs. 6.9, P<0.001) compared to patients with HCC (Table 1). The gene discussed is GPT; the disease is chronic hepatitis B virus infection.